Literature DB >> 26817127

[NONALCOHOLIC FATTY LIVER DISEASE: DIAGNOSTIC, SYMPTOMS, TREATMENT. GUIDELINES WERE APPROVED BY THE XV GASTROENTEROLOGICAL SCIENTIFIC SOCIETY OF RUSSIA IN 2015].

L B Lazebnik, V G Radchenko, E V Golovanova, L A Zvenigorodskaya, Yu V Konev, P V Seliverstov, S I Sitkin, E I Tkachenko, E K Aylamazayn, N N Vlasov, E A Kornienko, V P Novikova, L P Horoshinina, N V Zhestkova, L S Oreshko, O P Dudanova, V P Dobrica, L V Turyeva, O V Tirikova, N M Kozlova, S M Eliseev, R R Gumerov, E V Vencak.   

Abstract

According to the World Health Organization, it is recorded steady growth of the number of chronic liver diseases, including nonalcoholic fatty liver disease (NAFLD), in recent years. As an independent nosological entity, NAFLD is one of the risk factors for cardiovascular diseases, associated with abdominal-visceral obesity, peripheral insulin resistance (IR), and is regarded as the hepatic component of Metabolic syndrome (MS). Nowadays there are no generally accepted national standards for diagnosis and treatment of NAFLD for physicians, gen- eral practitioners, gastroenterologists in Russia. This was the essential reason in their development. The main reason of The guidelines development is the absence of generally accepted national standards for diagnosis and treatment of NAFLD for physicians, general practitioners, gastroenterologists in Russia. These guidelines are based on the global and local data of treatment experience of NAFLD, recently published in reviews, analytical studies in the literature. Guidelines are intended for physicians, general practitioners, gastroenterologists and contain the description of the preferred approaches to the provision of diagnostic, curative and preventive care of patients NAFLD. The quality of recommendations was grading according to the GRADE approach.

Entities:  

Mesh:

Year:  2015        PMID: 26817127

Source DB:  PubMed          Journal:  Eksp Klin Gastroenterol        ISSN: 1682-8658


  5 in total

1.  Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia.

Authors:  Igor V Maev; Aleksey A Samsonov; Liudmila K Palgova; Chavdar S Pavlov; Elena Shirokova; Kirill M Starostin
Journal:  BMJ Open Gastroenterol       Date:  2019-08-18

2.  Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study).

Authors:  Igor V Maev; Aleksey A Samsonov; Liudmila K Palgova; Chavdar S Pavlov; Elena I Vovk; Elena N Shirokova; Kirill M Starostin
Journal:  BMJ Open Gastroenterol       Date:  2020-01-13

3.  Clinical Manifestations and Diagnosis of Nonalcoholic Fatty Liver Disease.

Authors:  Mahmoodreza Khoonsari; Mohammadreza Mohammad Hosseini Azar; Ramak Ghavam; Khadijeh Hatami; Mosa Asobar; Ali Gholami; Abdolhalim Rajabi; Fahimeh Safarnezhad Tameshkel; Bahare Amirkalali; Masoudreza Sohrabi
Journal:  Iran J Pathol       Date:  2017-04-01

4.  Water-soluble pristine C60 fullerene attenuates acetaminophen-induced liver injury.

Authors:  Halyna Kuznietsova; Oksana Lynchak; Natalia Dziubenko; Tetyana Herheliuk; Yuriy Prylutskyy; Volodymyr Rybalchenko; Uwe Ritter
Journal:  Bioimpacts       Date:  2019-05-22

5.  Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia.

Authors:  Igor V Maev; Aleksey A Samsonov; Liudmila K Palgova; Chavdar S Pavlov; Elena N Shirokova; Elena I Vovk; Kirill M Starostin
Journal:  BMJ Open Gastroenterol       Date:  2020-03-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.